Accéder au contenu
Merck
Toutes les photos(1)

Documents

P-023

Supelco

Phentermine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H15N
Numéro CAS:
122-09-8
Poids moléculaire :
149.23
Numéro MDL:
MFCD00059195
Code UNSPSC :
41116107
ID de substance PubChem :
329820023
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

2-8°C

Chaîne SMILES 

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

Clé InChI

DHHVAGZRUROJKS-UHFFFAOYSA-N

Catégories apparentées

Description générale

A Snap-N-Spike® reference solution applicable for use in clinical toxicology or urine drug testing by LC-MS/MS or GC/MS. Phentermine, a phenethylamine analog, is a stimulant and an appetite suppressant. This drug is a constituent of the withdrawn anti-obesity medication fen-phen.

Application

  • Phentermine solution for weight loss research: Phentermine is extensively studied as an appetite suppressant in obesity treatment. Its effectiveness in weight loss regimens is often analyzed through pharmaceutical research, where the solution form facilitates precise dosing and control in clinical trials, enhancing the understanding of its pharmacodynamics and therapeutic potential (Ni et al., 2015).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Eva Manakova et al.
Neuro endocrinology letters, 33 Suppl 3, 179-182 (2013-01-29)
Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is
Two new drugs approved for obesity.
Annette M Johnson
South Dakota medicine : the journal of the South Dakota State Medical Association, 65(9), 356-357 (2012-10-17)
Prescrire international, 22(136), 61-64 (2013-04-18)
The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise. There are no drugs with a favourable harm-benefit balance in this setting. A fixed-dose combination of topiramate, an antiepileptic drug, and
Michael H Davidson et al.
The American journal of cardiology, 111(8), 1131-1138 (2013-02-05)
The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine (PHEN) and topiramate extended-release (TPM ER). In the 56-week, randomized, double-blind, placebo-controlled, multicenter CONQUER trial, PHEN/TPM ER demonstrated
David H Winslow et al.
Sleep, 35(11), 1529-1539 (2012-11-02)
To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA) in obese adults. This phase 2, randomized, double-blind, placebo-controlled study included 2-week screening and 28-week treatment
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique